Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)

作者： M.G Kris , R Herbst , D Rischin , P LoRusso , J Baselga

DOI: 10.1016/S0169-5002(00)80233-0

关键词: Lung cancer 、 Growth factor receptor inhibitor 、 Epidermal growth factor receptor 、 Tyrosine-kinase inhibitor 、 Phase i trials 、 Internal medicine 、 Endocrinology 、 Cancer research 、 Medicine 、 Tyrosine kinase 、 Non small cell